INmune Bio Says Remains On Track In Line With Prior Guidance To Complete Its Phase 2 Clinical Trial Involving The Use Of XPro For The Treatment Of Alzheimer's Disease In Patients With Biomarkers Of Neuroinflammation
InMune Bio表示仍按计划完成其2期临床试验,该试验涉及使用xPro治疗具有神经炎症生物标志物的患者的阿尔茨海默氏病